|Bid||1.4600 x 925800|
|Ask||1.5250 x 411200|
|Day's range||1.4650 - 1.6000|
|52-week range||1.3550 - 2.6800|
|Beta (5Y monthly)||-0.04|
|PE ratio (TTM)||20.89|
|Earnings date||23 Aug 2022 - 29 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.75|
Cogstate Limited ( ASX:CGS ) shareholders might understandably be very concerned that the share price has dropped 34...
Leading clinical and scientific experts in neurodegenerative diseases and pharmaceutical research will provide guidance to progress Cogstate’s strategyMelbourne, VIC, Australia; New Haven, CT, USA, June 14, 2022 (GLOBE NEWSWIRE) -- Cogstate (ASX.CGS) a leading neuroscience technology company, today announced the formation of a Scientific Advisory Board (SAB), comprising clinical and scientific experts in cognitive assessment and drug development. The SAB will work closely with the Cogstate scien
The big shareholder groups in Cogstate Limited ( ASX:CGS ) have power over the company. Large companies usually have...